Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare has approved Sandoz's recombinant human growth hormone somatropin injection, marking it the first biosimilar product approved in Japan, a MHLW Pharmaceutical Examination Division official confirmed June 26

You may also be interested in...



Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan

Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan

The company plans to launch six to seven new products by the end of the year, and 10 additional products in 2010.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC072026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel